![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C41H50N8O8 |
Molar mass | 782.899 g·mol−1 |
Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.[1]
In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.[2]
References
- ^ Rao, Huiying; Song, Guangjun; Li, Guangming; Yang, Yongfeng; Wu, Xiaofeng; Guan, Yujuan; Mao, Qing; Jiang, Xiangjun; Wang, Changyuan; Zhang, Ying; Jia, Jidong; Guo, Xiaolin; Li, Chenghao; Ning, Jing; Qin, Hong; Pan, Hai; Wei, Lai (2020). "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis. 27 (1): 45–51. doi:10.1111/jvh.13208. PMID 31520460.
- ^ Gao, Yanhang; Kong, Fei; Li, Guangming; Li, Cheng; Zheng, Sujun; Lin, Jianmei; Wen, Xiaofeng; Hu, Jinghua; Wang, Xiaozhong; Wu, Xiaofeng; Xing, Huichun; Jia, Jidong; Jia, Zhansheng; Guan, Yujuan; Li, Chenghao; Wu, Guicheng; Gao, Zhiliang; Mou, Zhuangbo; Ning, Qin; Mao, Qing; Yang, Yongfeng; Ning, Jing; Li, Li; Pan, Hai; Zhou, Desheng; Ding, Yanhua; Qin, Hong; Niu, Junqi (2020). "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International. 40 (11): 2685–2693. doi:10.1111/liv.14633. PMC 7702130. PMID 33047868.